NCT Number: NCT02904395
Feasability and Interest of Screening for Infantile Pompe's Diseases at Birth
Given the 100 fold increase of the incidence of Pompe's disease in Western French Guiana, the objective of the present study is to implement systematic screening in newborns in French Guiana in order to start treatment before the muscular and cardiac symptoms appear.
Looking for future studies?
Notify MeKey information
Conditions
Age range
Up to 2 day
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- newborn
Exclusion criteria
- parent refusal
Treatment and study plan
Primary outcomes
-
acid maltase activity
Time frame: At birth
The acid maltase enzyme activity is evaluated just after birth. If it is abnormal then PCR allows to identify signature mutations.
-
Signature mutation for pompe's disease
Time frame: At birth
The acid maltase enzyme activity is evaluated just after birth. If it is abnormal then PCR allows to identify signature mutations.
Sponsors and collaborators
Lead sponsor
Centre Hospitalier de Cayenne
Other
Registry information
Acronym: DEPIPOMP1
Important dates
- Study start
- 2014
- Primary completion
- 2014
- Study completion
- 2015
- First posted
- Sep 19, 2016
- Registry last updated
- Sep 19, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen
NCT04676373
Brain Diseases, Brain Diseases, Metabolic
China
View Trial DetailsPrevalence of Heterozygote Mothers for Pompe's Disease Among Mothers Having Delivered in French Guiana
NCT02903654
Brain Diseases, Brain Diseases, Metabolic
View Trial DetailsPompe Prevalence Study in Patients With Muscle Weakness Without Diagnosis
NCT00830583
Brain Diseases, Brain Diseases, Metabolic
Nice, France
View Trial DetailsChina Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
NCT06666413
Brain Diseases, Brain Diseases, Metabolic
Shanghai, China
View Trial Details